People · Operator
Named in public records as an officer, director or promoter · active 2012–2021 · Biotechnology, Software / Tech, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AIT Therapeutics, Inc. | — | Biotechnology | Series B | $77.5M | $132.7M | 2017 |
| BioSig Technologies, Inc. | — | Software / Tech | Series A | $65.7M | $3.4M | 2015 |
| Alliqua BioMedical, Inc. | — | Biotechnology | Series A | $52.6M | $100.1M | 2012 |
| NeuroClear Technologies, Inc. | — | Software / Tech | Series A | $14.9M | $298.2M | 2020 |
| Nexgel, Inc. | — | Biotechnology | Seed | $4.6M | $37.6M | 2020 |
| Kalytera Therapeutics, Inc. | — | Pharma | Pre-Seed | $2.2M | $35.9M | 2016 |
Jerome Zeldis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jerome Zeldis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kenneth Londoner | 3 | 5 |
| David Stefansky | 3 | 3 |
| Jeffrey O'Donnell | 2 | 7 |
| Richard Rosenblum | 2 | 6 |
| Samuel Navarro | 2 | 4 |
| Anthony Zook | 2 | 4 |
| Steve Chaussy | 2 | 2 |
| David Johnson | 1 | 35 |
| Patrick Gallagher | 1 | 11 |
| Mark Wagner | 1 | 9 |
| James Sapirstein | 1 | 7 |
| Steven Berger | 1 | 7 |
| Steven King | 1 | 6 |
| Roy Tanaka | 1 | 6 |
| Michael Dougherty | 1 | 6 |
| Jerome B. Zeldis | 1 | 5 |
| Dennis Purcell | 1 | 5 |
| Robert Farrell | 1 | 4 |
| David Grossman | 1 | 4 |
| Asher Holzer | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.